NEURACAP
M&A UpdateUpdated · 7 pages · Free to read

Clinical Laboratory Services M&A update, 14–28 September 2026

A bi-weekly update on Clinical Laboratory Services covering public market movers, company news and M&A activity for September 14–28, 2026. Built for operators, acquirers and advisors tracking coverage, coding and reimbursement developments alongside the sector's deal record.

For information only. Not an appraisal or a fairness opinion.

The deeper read: Clinical Laboratory Services Sector Outlook — September 2026

Key figures

Sector Median Move
+7.9%
20 covered names, close-to-close
S&P 500 Move
+0.8%
same period
GRAIL (GRAL) Period Return
+75.6%
Sep 14–28, 2026
Sector EV/Revenue Median
4.5x
CY2027E

Read the report

NeuraCap

BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › CLINICAL LABORATORY SERVICES

Regulatory Wins Lift the Leaders While the Deal Record Stays Quiet

This update covers movers, company announcements and transaction activity across Clinical Laboratory Services for September 14–28, 2026.

September 14–28, 2026

Prepared by NeuraCap AI · Confidential

Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28

Clinical Laboratory Services Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice

1

1 / 7

Executive summary

Over September 14–28, 2026, the Clinical Laboratory Services sector moved on regulatory and reimbursement news rather than transactions: 14 of 20 covered names rose, with a median move of +7.9% against the S&P 500's +0.8%. GRAIL, Inc. (GRAL) led with a +75.6% period return after an FDA advisory committee vote in favour, and Tempus AI, Inc. (TEM) rose +36.8% on licensing and clearance news. No new precedent transactions entered the record, leaving the listed comparable set, priced at a 4.5x sector median on EV/Revenue, as the reference point for pricing conversations.

Key findings

  • 14 of 20 covered names rose; median move was +7.9%, beating the S&P 500's +0.8%.
  • GRAIL (GRAL) rose +75.6%, including a +33.7% single-day move on Sep 21.
  • Tempus AI (TEM) rose +36.8% on licensing and clearance news.
  • No new precedent transactions entered the record during the period.

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01
    BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

    HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › CLINICAL LABORATORY SERVICES

    Cover slide introducing the Clinical Laboratory Services bi-weekly industry events and M&A update for September 14–28, 2026.

    We open this bi-weekly update on Clinical Laboratory Services, covering regulatory wins, market moves and deal activity across the September 14–28, 2026 window. What follows walks through the movers, the catalysts behind them, and what the quiet deal record means for the sector.

    Everything on this page

    BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › CLINICAL LABORATORY SERVICES Regulatory Wins Lift the Leaders While the Deal Record Stays Quiet This update covers movers, company announcements and transaction activity across Clinical Laboratory Services for September 14–28, 2026. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Clinical Laboratory Services Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    THE BI-WEEKLY BOTTOM LINE

    Coverage, Coding and Clearance Milestones Set the Direction, Not Transactions

    Summarizes the two-week period, showing which covered names moved and the regulatory and coding developments behind those moves.

    Fourteen of the twenty covered names rose over the period, with the median move landing at +7.9% against the S&P 500's +0.8% — a gap that tracks closely with companies putting a regulatory or reimbursement milestone on the record. GRAIL, Inc. (GRAL) led with a +75.6% period return, including a +33.7% single-day move on Sep 21, while Tempus AI, Inc. (TEM) advanced +36.8% on a run of licensing and clearance news. A Sep 23 report on CMS's 2027 fee schedule plans moved the reimbursement conversation forward, and CareDx, Inc (CDNA) rose +23.4% over the window. No new transactions entered the precedent record, so the message for this period is clear: coverage and coding decisions, not deals, set the direction.

    Everything on this page

    THE BI-WEEKLY BOTTOM LINE Coverage, Coding and Clearance Milestones Set the Direction, Not Transactions The two-week period in one page · 20 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Clinical Laboratory Services Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 14 of 20 Covered Names Rose; The Median Move Was +7.9% The covered set ran ahead of the S&P 500's +0.8% over the two-week period. The gains clustered in names that put a regulatory or reimbursement development on the record inside the window. 2 Regulatory Decisions Did the Heavy Lifting GRAIL, Inc. (GRAL), a Premium-tier name in NeuraCap's standing sector view, rose +75.6% over the period with a +33.7% single-day move on Sep 21. Tempus AI, Inc. (TEM) rose +36.8% across a run of licensing and clearance announcements. 3 The 2027 Fee Schedule Moved into the Conversation A Sep 23 Benzinga item reported that CMS plans to align 2027 clinical laboratory fee schedule rates with private payer rates, an estimated $1b of Medicare savings, and read the change differently for BillionToOne, Inc. (BLLN) and CareDx, Inc (CDNA). CareDx rose +23.4% over the period. 4 The Transaction Record Added No New Entries Nothing new landed in the precedent set during the window, so the listed comparable group remains the reference. NeuraCap's standing lens for the sector is EV / Revenue on CY2027E, with a 4.5x sector median. +85.6% Best mover — YDES worst: IMDX -20.9% · 14 up / 6 down of 20 covered +7.9% Sector median two-week return vs S&P 500 +0.8%

  3. 03
    PUBLIC MARKET MOVERS

    The Biggest Moves Followed Decisions on Coverage, Coding and Clearance

    Ranks the biggest close-to-close share price moves and links them to recorded regulatory and reimbursement catalysts.

    The period's biggest share price moves cluster around companies that posted a regulatory or reimbursement catalyst inside the window, against a materiality bar of ±13.5% sector-relative. GRAIL, Inc. (GRAL) moved +75.6%, Tempus AI, Inc. (TEM) moved +36.8%, and CareDx, Inc (CDNA) moved +23.4%, all well above the sector median of +7.9% and the S&P 500's +0.8%. Each move links back to a filing or headline recorded in the window, and where no driver is recorded the page says so plainly. For operators and investors, this confirms that the market is pricing coverage and coding news in real time, not waiting for deal announcements.

    Everything on this page

    PUBLIC MARKET MOVERS The Biggest Moves Followed Decisions on Coverage, Coding and Clearance Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median +7.9% · S&P 500 +0.8% · materiality bar ±13.5% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Clinical Laboratory Services Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median +7.9% YD Bio Limited Ordinary Shares (YDES) +85.6% No notable in-window news was identified that clearly explains the move. The +85.6% two-week gain ran well ahead of the +7.9% median across covered names. Smaller diagnostics names can travel a long way from the covered-set median inside a single two-week window. UNEXPLAINED GRAIL, Inc. (GRAL) +75.6% Shares moved following Reuters' Sep 21 report that FDA staff reviewers flagged no major concerns on the Galleri multi-cancer early detection test, and then the Sep 23 advisory committee vote in favour of approval announced by the company. For screening assets, the regulatory milestone is the commercial unlock, and the market prices it on the day it lands. COMPANY-SPECIFIC Tempus AI, Inc. (TEM) +36.8% The move appears to reflect a run of in-window announcements: an extended data licence and a new licence covering a partner's RNA foundation model on Sep 21, followed by FDA 510(k) clearance for the Tempus ECG-MR AI product on Sep 28. A biopharma data franchise alongside clinical testing is being valued as a second earnings engine, not a side line. COMPANY-SPECIFIC Insight Molecular Diagnostics Inc. (IMDX) -20.9% No notable in-window news was identified that clearly explains the move. The -20.9% two-week move sat well below the +7.9% median across covered names. Direction was not uniform: six of the twenty covered names finished the period lower. UNEXPLAINED

  4. 04
    MAJOR NEWS & INDUSTRY CATALYSTS

    Companies Spent the Period Building Coverage, Coding and Menu

    Lists the two-week period's highest-impact company announcements on coverage, coding and menu expansion.

    Over the two weeks, companies in the space built their evidence file through coverage, coding and menu decisions rather than deal announcements. GRAIL, Inc. (GRAL) cleared an FDA advisory committee vote in favour, and Tempus AI, Inc. (TEM) added 510(k) clearance and new data licensing to its record. A Sep 23 report also flagged CMS's plan to align the 2027 clinical laboratory fee schedule with private payer rates, an estimated $1b of Medicare savings, read differently for BillionToOne, Inc. (BLLN) and CareDx, Inc (CDNA). These are the catalysts behind the market moves we just walked through, and they are the evidence advisors and operators should be tracking closely.

    Everything on this page

    MAJOR NEWS & INDUSTRY CATALYSTS Companies Spent the Period Building Coverage, Coding and Menu The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Clinical Laboratory Services Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 22 · NEWS · PRNewsWire Castle Biosciences to open a new laboratory facility in Scottsdale, Arizona Added lab capacity is a bet on accessioned volume growth and on cost per accession falling as that volume absorbs a fixed footprint. Capacity decisions are being taken ahead of volume, which only works where the ordering base is already expanding. Sep 22 · NEWS · PRNewsWire Lucid Diagnostics advances EsoGuard payment basis and wins a new Category III code for EsoCheck A Medicare advisory panel recommendation on the gapfill payment basis plus a new CPT code speak directly to reimbursement durability, the gate between a test performed and a dollar collected. Coding and payment decisions, taken one assay at a time, are where specialty labs build defensible economics. Sep 22 · NEWS · Business Wire Natera wins Japanese regulatory approval for Signatera as a companion diagnostic in bladder cancer A companion diagnostic approval in a second major market widens the indication footprint and strengthens the biopharma side of the franchise. Geographic and indication expansion on an existing assay is a cheaper route to revenue than a new menu build. Sep 21 · NEWS · Business Wire Tempus extends its data licence and adds a new licence for a partner's RNA foundation model Data licensing turns the clinical testing archive into contracted revenue that behaves differently from accessioned volume. Laboratory data assets are being contracted, and that revenue line is now part of how these businesses are framed. Sep 18 · NEWS · Business Wire Natera presents lung cancer MRD data showing strong prognostic value for Signatera Clinical utility evidence at a major conference is the input to guideline inclusion, which is what converts ordering interest into routine ordering behaviour. Evidence programmes remain the long-cycle cost that decides which assays earn payer coverage. Sep 16 · NEWS · GlobeNewsWire Executives disclose roughly $629,000 of open-market share purchases after positive Phase 2a results Open-market buying by management alongside a clinical readout is a visible signal about how insiders view the company's position after the data. In evidence-stage names, insider action is read as a supplement to the data, not a substitute for coverage.

  5. 05
    M&A & STRATEGIC ACTIVITY

    Buyers Stayed on the Sidelines While Operators Advanced Their Own Evidence

    Reviews the state of transaction activity, noting no new precedent deals were recorded in the window.

    The precedent transaction set held at 40 recorded deals over the two-week period, with no new entries added to the record. Deal multiples in that set are LTM at announcement where disclosed, and our read of why prior deals happened remains a NeuraCap interpretation of the recorded evidence, not fact. With buyers on the sidelines, operators used the window to advance their own regulatory and reimbursement evidence instead, which is exactly what showed up in the price moves. For acquirers and advisors, the listed comparable group — priced at a 4.5x sector median on EV/Revenue for CY2027E — remains the reference point until new deals land.

    Everything on this page

    M&A & STRATEGIC ACTIVITY Buyers Stayed on the Sidelines While Operators Advanced Their Own Evidence September 14–28, 2026 · precedent transactions: 40 recorded deals Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Clinical Laboratory Services Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 No Material Transactions Announced No material sector transactions were announced during the period. The observable buyer activity was menu-level: Veracyte, Inc. (VCYT) announced on Sep 14 that it had acquired a urinary tumour DNA testing platform to widen its urology portfolio. A quiet two-week period is information: buyer appetite, financing conditions and seller expectations all read through a period with no new deals. The precedent transactions alongside still frame what buyers have paid. 40 Recorded precedent transactions the reference set buyers and sellers price against

  6. 06
    WHAT IT MEANS

    What the Period Means for Operators, Buyers and Advisors

    Translates the period's evidence into operational takeaways for operators, acquirers and advisors.

    For owners and operators, the period rewarded reimbursement conversion — the KPIs to track are accessioned volume by channel and average reimbursement per test. For acquirers, the absence of new precedent transactions means pricing conversations continue to run off the listed comparable set, and that set moved, with 14 of 20 covered names higher and a +7.9% median. For advisors, the evidence to lead with is concrete: GRAIL, Inc. (GRAL)'s advisory committee vote in favour, and Tempus AI, Inc. (TEM)'s 510(k) clearance and new data licensing. Taken together, these are observations on where the evidence points, not recommendations, and they set up the coverage-first conversations we expect to continue.

    Everything on this page

    WHAT IT MEANS What the Period Means for Operators, Buyers and Advisors The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Clinical Laboratory Services Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / Revenue (CY2027E) median 4.5x 22 companies in the study 3 valuation tiers Standing thesis: Clinical Laboratory Services spans scaled lab networks, specialty diagnostics and adjacent models FOR OWNERS & OPERATORS Reimbursement Conversion Is What the Period Rewarded Companies in the space traded higher on coverage, coding and clearance milestones. The KPIs behind that are the familiar ones: accessioned volume by clinical, biopharma and screening channel, average reimbursement per test FOR ACQUIRERS The Listed Comparable Set Is Still the Reference Point No new precedent transactions entered the record during the two-week period, so pricing conversations continue to run off visible listed comparables. Those comparables moved: 14 of 20 covered names rose and the median move was +7.9%. FOR ADVISORS Lead with the Coverage and Evidence File The period's dominant theme was regulatory and reimbursement progress, not transactions. The evidence to lead with is concrete: an FDA advisory committee vote in favour for GRAIL, Inc. (GRAL), 510(k) clearance and new data licensing at Tempus AI, Inc.

  7. 07
    SOURCES & METHODOLOGY

    Sources, Methodology and Important Notice

    Explains the sources, methodology and evidentiary standards behind the update.

    This update draws only on figures that link back to a recorded filing, press release or established outlet inside the window. Every driver attribution is a calibrated NeuraCap read of that evidence, not asserted causation, so you can trace each figure back to its source before acting on it.

    Everything on this page

    SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Clinical Laboratory Services Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. 2 names below the floor were excluded from movers and statistics for this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T164450Z_538_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: prnewswire.com · businesswire.com · globenewswire.com

Sources and methodology

This update covers Clinical Laboratory Services over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 20 listed companies whose core business is Clinical Laboratory Services under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Aclaris Therapeutics, Inc. (ACRS), Adaptive Biotechnologies Corporation (ADPT), BillionToOne, Inc. (BLLN), CareDx, Inc (CDNA), Castle Biosciences, Inc. (CSTL), Quest Diagnostics Incorporated (DGX), Fulgent Genetics, Inc. (FLGT), Guardant Health, Inc. (GH), GRAIL, Inc. (GRAL), Insight Molecular Diagnostics Inc. (IMDX), Labcorp Holdings Inc. (LH), Lucid Diagnostics Inc. (LUCD), NeoGenomics, Inc. (NEO), Natera, Inc. (NTRA), Prenetics Global Limited (PRE), Tempus AI, Inc. (TEM), Veracyte, Inc. (VCYT), GeneDx Holdings Corp. (WGS), Exagen Inc. (XGN), YD Bio Limited Ordinary Shares (YDES). 2 names below the floor were excluded from the statistics: MDXH, SERA.

Window and company universe

This update covers Clinical Laboratory Services over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 20 listed companies whose core business is Clinical Laboratory Services under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Aclaris Therapeutics, Inc. (ACRS), Adaptive Biotechnologies Corporation (ADPT), BillionToOne, Inc. (BLLN), CareDx, Inc (CDNA), Castle Biosciences, Inc. (CSTL), Quest Diagnostics Incorporated (DGX), Fulgent Genetics, Inc. (FLGT), Guardant Health, Inc. (GH), GRAIL, Inc. (GRAL), Insight Molecular Diagnostics Inc. (IMDX), Labcorp Holdings Inc. (LH), Lucid Diagnostics Inc. (LUCD), NeoGenomics, Inc. (NEO), Natera, Inc. (NTRA), Prenetics Global Limited (PRE), Tempus AI, Inc. (TEM), Veracyte, Inc. (VCYT), GeneDx Holdings Corp. (WGS), Exagen Inc. (XGN), YD Bio Limited Ordinary Shares (YDES). 2 names below the floor were excluded from the statistics: MDXH, SERA.

How the moves and statistics are computed

Each company's period move is the change in closing price from the last close before the window to the last close inside it (close-to-close). The sector median is the median of those moves across the covered names; the index return is computed the same way for the S&P 500 over the same dates. The largest single-day move inside the window is shown for each mover. Movers are the largest gainers and losers by period move; the attribution cards prefer movers whose in-window record explains the move. Movers carry the valuation tier assigned in the standing sector study (the latest NeuraCap sector outlook) where that study rated them.

Events, news and how a move is attributed

Company events are the 8-K filings made inside the window; news items are publisher-sourced headlines for the window, admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron's and peers). Video and social platforms are never used. A move is linked to an event only when the event falls inside the window and only in calibrated language; where nothing in the record explains a move, the update says so rather than speculating. Every event links to its source.

Transactions in the window and the trailing record

Transactions are taken from SEC filings by announcement date; 0 were announced inside the window. The trailing record of 40 recorded transactions provides the reference multiples (EV over last-twelve-month revenue or EBITDA at announcement, as disclosed). A value whose own citation describes something other than the price paid is not shown as the deal value; transactions where the acquirer and the target are the same entity are treated as reorganisations and excluded.

Sources

Prices and index levels are market data through September 28, 2026; filings are the companies' SEC filings on EDGAR; press releases are the companies' own; other news items are from the established outlets named on each card; Treasury yields are published by the U.S. Department of the Treasury. Every figure and every event in the update links to its record.

Interpretation and important notice

'Why it matters', 'why the deal happened' and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, labelled as such. The update is informational: it is not investment advice, not a recommendation to buy or sell any security and not an offer of any kind.

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Clinical Laboratory Services?

Company valuation reports run the same method against a single business — public or private.